Ascentage Pharma Group International (AAPG) Non-Current Deferred Tax Liability (2022 - 2025)

Ascentage Pharma Group International (AAPG) has disclosed Non-Current Deferred Tax Liability for 4 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • For Q4 2025, Non-Current Deferred Tax Liability rose 141.78% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $1.8 million, up 141.78%, while the annual FY2025 figure was $1.8 million, 149.39% up from the prior year.
  • Non-Current Deferred Tax Liability hit $1.8 million in Q4 2025 for Ascentage Pharma Group International, up from $747310.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $2.5 million in Q4 2022 and bottomed at $747310.0 in Q4 2024.
  • Average Non-Current Deferred Tax Liability over 4 years is $1.8 million, with a median of $2.0 million recorded in 2025.
  • Year-over-year, Non-Current Deferred Tax Liability plummeted 66.29% in 2024 and then soared 141.78% in 2025.
  • Ascentage Pharma Group International's Non-Current Deferred Tax Liability stood at $2.5 million in 2022, then decreased by 9.79% to $2.2 million in 2023, then plummeted by 66.29% to $747310.0 in 2024, then skyrocketed by 141.78% to $1.8 million in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $1.8 million, $747310.0, and $2.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.